169 related articles for article (PubMed ID: 20202593)
1. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation.
Mersereau J; Dooley MA
Rheum Dis Clin North Am; 2010 Feb; 36(1):99-108, viii. PubMed ID: 20202593
[TBL] [Abstract][Full Text] [Related]
2. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study.
Manger K; Wildt L; Kalden JR; Manger B
Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968
[TBL] [Abstract][Full Text] [Related]
3. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
4. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
[TBL] [Abstract][Full Text] [Related]
5. Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents.
Elizur SE; Chian RC; Pineau CA; Son WY; Holzer HE; Huang JY; Gidoni Y; Levin D; Demirtas E; Tan SL
Rheumatology (Oxford); 2008 Oct; 47(10):1506-9. PubMed ID: 18660508
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis?
Wetzels JF
Neth J Med; 2004 Nov; 62(10):347-52. PubMed ID: 15683089
[TBL] [Abstract][Full Text] [Related]
7. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.
Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A
Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312
[TBL] [Abstract][Full Text] [Related]
8. Successful pregnancy after cyclophosphamide therapy for lupus nephritis.
Lannes G; Elias FR; Cunha B; Jesus N; Klumb EM; Albuquerque EM; Ribeiro FM
Arch Gynecol Obstet; 2011 Mar; 283 Suppl 1():61-5. PubMed ID: 21331538
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG
Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
11. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury.
Oktay K; Sönmezer M; Oktem O; Fox K; Emons G; Bang H
Oncologist; 2007 Sep; 12(9):1055-66. PubMed ID: 17914075
[TBL] [Abstract][Full Text] [Related]
12. Should gonadotropin releasing hormone analogue be administered to prevent premature ovarian failure in young women with systemic lupus erythematosus on cyclophosphamide therapy?
Sinha R; Dionne JM
Arch Dis Child; 2008 May; 93(5):444-5. PubMed ID: 17908713
[No Abstract] [Full Text] [Related]
13. Prevention of gonadal damage during cytotoxic therapy.
Blumenfeld Z; Haim N
Ann Med; 1997 Jun; 29(3):199-206. PubMed ID: 9240625
[TBL] [Abstract][Full Text] [Related]
14. Pulse cyclophospamide in severe lupus nephritis: Southern Indian experience.
Das U; Dakshina Murty KV; Prasad N; Prayag A
Saudi J Kidney Dis Transpl; 2010 Mar; 21(2):372-8. PubMed ID: 20228536
[TBL] [Abstract][Full Text] [Related]
15. [Intermittent intravenous administration of cyclophosphamide in patients with lupus nephritis].
Morović-Vergles J; Galesić K; Dancuo I; Vergles D
Acta Med Croatica; 2004; 58(1):13-7. PubMed ID: 15125388
[TBL] [Abstract][Full Text] [Related]
16. Intravenous cyclophosphamide in lupus nephritis.
Leondike MR; Shattuck MA
J Intraven Nurs; 1993; 16(1):23-7. PubMed ID: 8437043
[TBL] [Abstract][Full Text] [Related]
17. [Intermittent intravenous cyclophosphamide application in patients with systemic lupus erythematosus].
Anić B; Crkvencić N; Mayer M; Bosnić D; Sentić M; Markeljević J; Cikes N
Lijec Vjesn; 1999; 121(9-10):283-8. PubMed ID: 19658369
[TBL] [Abstract][Full Text] [Related]
18. [Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide].
Liang LQ; Qiu Q; Yang XY; Xu HS; Ye YJ; Zhan ZP; Lian F; Chen DY
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1009-11. PubMed ID: 18754430
[TBL] [Abstract][Full Text] [Related]
19. [Plasmapheresis in a case of necessary discontinuation of cyclophosphamide in the treatment of severe lupus nephritis].
Saracyn M; Korsak J; Wańkowicz Z
Pol Merkur Lekarski; 2004 Aug; 17(98):162-4. PubMed ID: 15603328
[TBL] [Abstract][Full Text] [Related]
20. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.
Blumenfeld Z
Oncologist; 2007 Sep; 12(9):1044-54. PubMed ID: 17914074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
